Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients With Chronic Inducible Urticaria
Celldex宣布完成巴佐沃利单抗治疗慢性诱发性荨麻疹患者的2期研究的入组
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients With Chronic Inducible Urticaria
Celldex宣布完成巴佐沃利单抗治疗慢性诱发性荨麻疹患者的2期研究的入组
使用浏览器的分享功能,分享给你的好友吧